Table 1

Overview of CPGs and modules analysed, number of interviews, and the role and specialty of interviewees

Localisation	Module	Publication date	Approach	Options discussed in recommendations (n)	Strength of recommendations					Role and specialty of interviewees
					In favour		Neutral	Against
					Strong	Weak		Weak	Strong
Breast cancer	Ductal Carcinoma In Situ (DCIS)	IKNL, unpublished concept (27 February 2017)	GRADE	5	1	0	3	0	1	Surgeon (n=2) Radiotherapist (n=2)
	Endocrine therapy	IKNL, unpublished concept (27 March 2017)	GRADE	11	4	7	0	0	0	None
										IKNL supervisor (n=1)* Patient representative (n=1)
Colorectal cancer	T1 carcinoma in polyp	16 April 2014 (version 3)	Evidence-based	3	1	2	0	0	0	Surgeon (n=1) Gastroenterologist (n=1)
	Adjuvant chemotherapy	16 April 2014 (version 3)	Evidence-based	6	4	2	0	0	0	Oncologist (n=1)
										IKNL supervisor (n=1)* Patient representative (n=1)
Resectable non-small cell lung cancer (NSCLC)	Stereotactic radiotherapy	16 April 2014 (version 3)	Evidence-based (2011) and consensus-based (2013)	3	1	1	0	1	0	Radiotherapist (n=3)†
	(Neo)adjuvant radiotherapy	16 April 2014 (version 3)	Evidence-based (2011) and consensus-based (2013)	4	1	2	0	0	1	Radiotherapist (n=1)†
										IKNL supervisor (n=1)
n=3	n=6			n=32	n=12	n=14	n=3	n=1	n=2	IKNL supervisor (n=2) Patient representative (n=2) Radiotherapist (n=5) Surgeon (n=3) Oncologist (n=1) Gastroenterologist (n=1)

*Interviewed once, both about the breast cancer and the colorectal carcinoma guidelines.
†One radiotherapist was interviewed once about two modules of the NSCLC CPG.
CPG, clinical practice guideline; GRADE, Grading of Recommendations Assessment, Development and Evaluation; IKNL, Netherlands Comprehensive Cancer Organisation.